Actelion says year off to good start with new drug launch
ZURICH, April 17 (Reuters) Actelion Ltd launch of it canada goose store new Canada Goose Online lung drug has got off to a good start and as a canada goose uk black friday result the buy canada goose jacket cheap Swiss firm might raise its earnings forecast at mid year, it said on cheap Canada Goose Thursday after reporting a better than expected first quarter canada goose black friday sale result.
Europe biggest biotech drugs company is banking on a strong ramp up in sales of the new drug, Opsumit, a treatment for pulmonary arterial hypertension (PAH), to boost core earnings in the low single digit percentage range this year.
But the company said it buy canada goose jacket would review this earnings forecast by mid year following a start Canada Goose Jackets to the year.
really think that we cheap canada goose uk should guide up, but how much canada goose coats up that a question and that what we will be in a position to do in the next quarter, Chief Executive Jean Paul Clozel told Reuters.
The Swiss company notched up 15 million Swiss francs uk canada goose ($17 million) in sales for Opsumit in the first quarter, but stressed this figure does not reflect underlying demand for the drug since the company offers a portion of the medicine for free in the United States under a patient access programme.
Jefferies analyst Peter Welford described Canada Goose Outlet the more than 2,300 canada goose uk outlet patients already on the drug, mostly in the United States, as and suggested Canada Goose Parka annual sales in excess of 165 million Swiss francs ($187 million).
a very very significant success, you can imagine that 2,300 patients a few months after the launch was something I was not expecting, Clozel said.
Shares in Actelion, which trade at 17.7 times forecast earnings compared with a peer medium of 14.5 times, were uk canada goose outlet indicated up 3.5 percent in premarket trade.
BETTER THAN TRACLEER? The company expects Opsumit peak sales to eclipse those of its current flagship Canada Goose Coats On Sale product Tracleer, which also treats PAH but Canada Goose sale goes off patent from 2015 and has faced growing competition from Gilead Letairis. Jefferies Welford forecasts peak sales for Opsumit of $2.2 billion.
Sales of Tracleer, rose 2 percent in the quarter canada goose uk shop to canada goose 383 million francs, due to Canada Goose online strong demand in countries where Opsumit is not yet on the market.
In countries where canada goose coats on sale Opsumit has launched, such as the United States, weekly new Tracleer prescriptions are down by canadian goose jacket two thirds or more, Actelion spokesman Roland Haefeli said. The drug is also available in Canada, Germany, Austria, Switzerland, Denmark and Norway.
Actelion canada canadagooseonlineshop goose clearance sale reported an 8 percent rise in first quarter product sales to 469 million francs, generating a net profit of 128 million francs, up 30 percent on the year.
Analysts canada goose clearance https://www.canadagooseonlineshop.co.uk in a Reuters poll had forecast product sales of 435 million and net profit of 98.5 million.
Investors are now turning their attention canada goose factory sale to Phase III trial results for selexipag, another PAH drug, and Actelion said it would present top line results the next few weeks.
For now Actelion maintained its forecast for a low single digit percentage increase in core earnings at constant currencies this year. It also expects single digit core earnings growth in 2015. ($1=0.8816 Swiss francs) (Reporting by Caroline Copley; Editing by Greg Mahlich).
